Sabril® (vigabatrin) – Expanded indication
January 24, 2020 - The FDA approved Lundbeck’s Sabril (vigabatrin), as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.
Top